Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 9.6% – Here’s What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE) dropped 9.6% during mid-day trading on Wednesday . The company traded as low as $26.96 and last traded at $29.32. Approximately 111,833 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 298,220 shares. The stock had previously closed at $32.42.

Analyst Ratings Changes

MAZE has been the topic of a number of research reports. Wedbush initiated coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 price target on the stock. Guggenheim boosted their target price on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, September 15th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Maze Therapeutics in a report on Thursday, September 18th. Finally, BTIG Research boosted their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $33.83.

Maze Therapeutics Trading Down 7.1%

The business’s 50 day moving average is $24.94 and its 200 day moving average is $16.89. The stock has a market capitalization of $1.32 billion and a PE ratio of -1.49.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.02.

Insider Activity at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Investors Weigh In On Maze Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its position in Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after buying an additional 1,455 shares during the period. CWM LLC purchased a new stake in Maze Therapeutics in the 2nd quarter valued at about $28,000. New York State Common Retirement Fund purchased a new stake in Maze Therapeutics in the 1st quarter valued at about $25,000. Legal & General Group Plc boosted its position in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after buying an additional 3,774 shares during the period.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.